Analysts Set The Clorox Company (NYSE:CLX) Price Target at $144.47

Shares of The Clorox Company (NYSE:CLXGet Rating) have been given an average recommendation of “Hold” by the eighteen brokerages that are presently covering the firm, MarketBeat.com reports. Eight analysts have rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $144.47.

CLX has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Clorox from $162.00 to $148.00 and set a “hold” rating for the company in a research note on Friday, February 4th. Wells Fargo & Company cut their price objective on shares of Clorox from $150.00 to $120.00 and set an “underweight” rating for the company in a research note on Tuesday, March 15th. The Goldman Sachs Group cut their price objective on shares of Clorox from $145.00 to $127.00 in a research note on Tuesday, March 29th. JPMorgan Chase & Co. dropped their price target on shares of Clorox from $137.00 to $123.00 in a research report on Wednesday, March 30th. Finally, Zacks Investment Research cut shares of Clorox from a “hold” rating to a “strong sell” rating and set a $124.00 price target for the company. in a research report on Tuesday, February 8th.

CLX stock traded down $0.76 during midday trading on Friday, reaching $145.69. The company had a trading volume of 27,342 shares, compared to its average volume of 1,551,218. The company has a debt-to-equity ratio of 3.84, a current ratio of 0.67 and a quick ratio of 0.36. Clorox has a 1 year low of $127.02 and a 1 year high of $196.65. The company has a market capitalization of $17.90 billion, a P/E ratio of 73.31, a P/E/G ratio of 5.76 and a beta of 0.23. The firm has a 50-day moving average price of $141.64 and a 200-day moving average price of $159.45.

Clorox (NYSE:CLXGet Rating) last announced its quarterly earnings data on Thursday, February 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.78 by ($0.12). Clorox had a net margin of 3.49% and a return on equity of 86.36%. The business had revenue of $1.69 billion during the quarter, compared to analysts’ expectations of $1.68 billion. During the same period last year, the company posted $2.03 EPS. On average, equities analysts predict that Clorox will post 4.24 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 13th. Shareholders of record on Wednesday, April 27th will be issued a $1.16 dividend. The ex-dividend date is Tuesday, April 26th. This represents a $4.64 annualized dividend and a yield of 3.18%. Clorox’s dividend payout ratio (DPR) is presently 233.17%.

Several institutional investors have recently modified their holdings of the stock. Martin Capital Partners LLC increased its stake in shares of Clorox by 1.9% in the 4th quarter. Martin Capital Partners LLC now owns 3,022 shares of the company’s stock worth $527,000 after acquiring an additional 57 shares in the last quarter. Strategy Asset Managers LLC increased its stake in shares of Clorox by 3.6% in the 3rd quarter. Strategy Asset Managers LLC now owns 1,670 shares of the company’s stock worth $277,000 after acquiring an additional 58 shares in the last quarter. Legacy Financial Advisors Inc. increased its stake in shares of Clorox by 5.6% in the 3rd quarter. Legacy Financial Advisors Inc. now owns 1,233 shares of the company’s stock worth $204,000 after acquiring an additional 65 shares in the last quarter. International Assets Investment Management LLC increased its stake in shares of Clorox by 2.9% in the 3rd quarter. International Assets Investment Management LLC now owns 2,360 shares of the company’s stock worth $391,000 after acquiring an additional 66 shares in the last quarter. Finally, Corient Capital Partners LLC increased its stake in shares of Clorox by 4.4% in the 3rd quarter. Corient Capital Partners LLC now owns 1,585 shares of the company’s stock worth $262,000 after acquiring an additional 67 shares in the last quarter. Institutional investors own 77.34% of the company’s stock.

About Clorox (Get Rating)

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brand names; professional cleaning and disinfecting products under the CloroxPro, Clorox Healthcare, and Clorox Total 360 brand names; professional food service products under the Hidden Valley brand name; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brand names in the United States.

See Also

Analyst Recommendations for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.